Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Saba Yari"'
Publikováno v:
Case Reports in Clinical Practice, Vol 6, Iss 4 (2021)
Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder. Tyrosine Kinase JAK2 (JAK2 V617F) mutation occurs in nearly 60% of Essential Thrombocythemia (ET) patients. Both diseases produce impaired platelet. We describe a case with ET followin
Externí odkaz:
https://doaj.org/article/42c1c61df77c47dd9b51ed6d199cff91
Autor:
saba yari
Publikováno v:
Asian Pacific Journal of Cancer Care, Vol 4, Iss 1 (2018)
Objective: Quantification of the BCR-ABL transcript is recommended to follow-up CML patients that treated by Imatinib mesylate (IM) as a tyrosine kinase inhibitor. BCR-ABL transcripts have been recognized as a molecular marker for response to therapy
Externí odkaz:
https://doaj.org/article/70a6327712ca41eda21041819682813b
Publikováno v:
Asian Pacific Journal of Cancer Care, Vol 4, Iss 1, Pp 1-1 (2018)
Objective: Quantification of the BCR-ABL transcript is recommended to follow-up CML patients that treated by Imatinib mesylate (IM) as a tyrosine kinase inhibitor. BCR-ABL transcripts have been recognized as a molecular marker for response to therapy
Externí odkaz:
https://doaj.org/article/95c45f823e0a46778cf96a9f8f74db24
Publikováno v:
Case Reports in Clinical Practice, Vol 6, Iss 4 (2021)
Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder. Tyrosine Kinase JAK2 (JAK2 V617F) mutation occurs in nearly 60% of Essential Thrombocythemia (ET) patients. Both diseases produce impaired platelet. We describe a case with ET followin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a65477c5f5d3070c63d0fc76fa4d42
https://doi.org/10.18502/crcp.v6i4.7853
https://doi.org/10.18502/crcp.v6i4.7853
Publikováno v:
Biomedical Research and Therapy. 5:2365-2369
Palbociclib, an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6), has been approved for metastatic breast cancer (mBC) treatment of hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative. The study report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f11db60a03de7902ff68b0642137d5cb
https://doi.org/10.15419/bmrat.v5i6.448
https://doi.org/10.15419/bmrat.v5i6.448